ABSORB as Good as Xience

ACC Conference Reporter

TCT 2015 | SAN FRANCISCO — A slew of studies in the ABSORB clinical series — ABSORB II, ABSORB III, and ABSORB-China — were reported at TCT 2015 today and once again the everolimus-eluting bioresorbable scaffold was non-inferior to an everolimus-eluting metal stent (Xience). Read More >>>

Keywords: Transcatheter Cardiovascular Therapeutics


< Back to Listings